Why Is GRAIL INC EQUITY Equity (GRAL) Stock Down Today?

Why GRAL stock is down today

GRAIL Inc (GRAL) fell 8.66% to $68.94 in afternoon trading on June 5 as investors reacted to a scheduled FDA advisory committee review of the company's premarket approval application for its Galleri multi-cancer early detection test. The session saw a sharp decline from an opening price of $75.65, with the stock hitting a session low of $68.69. The stock is trading near the lower end of its 52-week range of $29.95 to $118.84.

What Happened

The FDA advisory committee is set to evaluate GRAIL’s application on September 23. This event represents a key regulatory milestone for the company, which has yet to achieve profitability despite a 23.1% year-to-date revenue increase. The stock’s decline came as investors weighed the risk of a potential delay or rejection of the PMA. The company’s recent collaboration with Priority Health to offer Galleri to employer groups and its Q2 financial results, where it beat revenue estimates, were not enough to offset the bearish sentiment. Mizuho maintained a neutral stance on the stock but raised its price target to $65. Meanwhile, the Chief Growth Officer sold shares on June 4, adding to the cautious tone.

What The Data Shows

The stock traded at 0.5 times its 3-month average volume, with 0.3 million shares changing hands. The company has a market cap of $2.8 billion and a net margin of -236.9%. Its beta of 3.25 indicates high volatility relative to the market. The 30-day average sentiment score improved to 59 out of 100 in the last week, but the stock remains unprofitable with an EPS of -9.75 for the trailing twelve months.

What To Watch

Investors should monitor the FDA advisory committee meeting on September 23 for any developments regarding the Galleri test’s regulatory path. Coverage breadth is also a key factor, as only one story has been published in the last 36 hours.